May 11, 2020
CA Appellate Court Rules Risperdal Not Federally Preempted | Sanders Phillips Grossman, LLC
Sep 11, 2019
Similar Response Rate but Higher Degrees of Clinical Improvement Were More Likely to Achieve With Cariprazine Compared to Risperidone - A Study by Gedeon Richter Plc
Jul 23, 2019
Schizophrenia Drugs Market Growth, Trends, and Forecast 2019-2024
Mar 28, 2019
Luye Pharma's Rykindo® Expected to Be the First Chinese Innovative Drug to Receive U.S. FDA Approval
Feb 27, 2019
Indivior Announces Launch of PERSERIS(TM) (risperidone) for the Treatment of Schizophrenia in Adults
Dec 30, 2018
Luye Pharma Announces Innovative Drug - Risperidone Extended Release Microspheres for Injection has Reached Final Stage of NDA Process
Dec 19, 2018
Commercial Launch Plans Announced for PERSERIS(TM) (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Dec 13, 2018
Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
Aug 30, 2018
DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
Jul 27, 2018
FDA Approves PERSERIS(TM) (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
Dec 13, 2017
DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot
Dec 12, 2017
Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot
Oct 02, 2017
DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement